文献速递冠心病血脂与心血管预防

糖尿病患者的FFR引导PCI与冠状动脉旁路移植术比较

FFR-Guided Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Diabetes.
PubMed 文献 · JAMA Cardiol · 2025-01-01

FAME 3试验预设亚组分析,纳入1500例三支血管病变患者(糖尿病428例,28.5%),比较FFR引导PCI与CABG。SYNTAX≥23时PCI风险更高,与糖尿病状态无关。

要点

  • 糖尿病患者3年MACCE风险高于非糖尿病患者,胰岛素治疗者尤甚。
  • 糖尿病与非糖尿病患者中,FFR引导PCI的MACCE风险均高于CABG,无显著交互作用。
  • SYNTAX评分≥23时PCI的MACCE风险高于CABG,与糖尿病状态无关。

核心结论

  • 在FAME 3试验预设亚组分析中,CABG相对FFR引导PCI的获益在糖尿病与非糖尿病患者中相似。

研究设计与样本

  • FAME 3试验为研究者发起的随机临床试验,在48个中心开展,2014年8月至2019年12月纳入不累及左主干的3支血管病变患者。
  • 本分析为预设亚组分析,共纳入1500例患者,其中糖尿病428例(28.5%),平均年龄65.1岁(SD 8.4),女性265例(17.7%)。
  • 干预为FFR引导PCI使用当代药物洗脱支架或CABG,随访至3年。

主要发现

  • 糖尿病患者3年MACCE风险高于非糖尿病患者,接受胰岛素治疗者尤甚。
  • SYNTAX评分<23时PCI与CABG的MACCE无显著差异;SYNTAX评分≥23时PCI的MACCE风险高于CABG,与糖尿病状态无关。

关键数值与推荐

  • 主要终点为3年MACCE,定义为全因死亡、心肌梗死、卒中或再次血运重建的复合终点。
  • 糖尿病定义为FAME 3试验纳入的428例患者(28.5%)。
  • SYNTAX评分低危定义为<23,中高危定义为≥23。

临床怎么用

  • 在三支血管病变患者中,糖尿病状态不应作为选择CABG优于FFR引导PCI的唯一依据。
  • SYNTAX评分≥23时,无论是否合并糖尿病,CABG可能较FFR引导PCI降低MACCE风险。
  • 糖尿病患者接受FFR引导PCI时,需关注其较高的3年MACCE风险,尤其是胰岛素治疗者。

局限性

  • 本分析为FAME 3试验的预设亚组分析,糖尿病亚组样本量有限。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Outcomes in patients with diabetes after fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) using current-generation drug-eluting stents (DES) compared with coronary artery bypass grafting (CABG) are unknown. OBJECTIVES: To investigate the relative treatment effect of PCI vs CABG according to diabetes status with respect to major adverse cardiac and cerebrovascular events (MACCE) at 3 years and to evaluate the impact of the SYNTAX score. DESIGN, SETTING, AND PARTICIPANTS: This is a prespecified subgroup analysis of the FAME (Fractional Flow Reserve vs Angiography for Multivessel Evaluation) 3 trial, an investigator-initiated, randomized clinical trial conducted at 48 centers worldwide. The FAME 3 trial enrolled patients with 3-vessel coronary artery disease not involving the left main undergoing coronary revascularization between August 2014 and December 2019. Data analysis was conducted in August 2023. Clinical follow-up was performed at hospital discharge and at 1 month, 6 months, 1 year, 2 years, and 3 years after randomization. INTERVENTION: Either FFR-guided PCI with current-generation DES or CABG. MAIN OUTCOMES AND MEASURES: The primary end point was MACCE, defined as the composite of all-cause death, myocardial infarction, stroke, or repeat revascularization at 3 years. RESULTS: Of 1500 total patients enrolled, mean (SD) patient age was 65.1 (8.4) years, and 265 patients (17.7%) were female. The FAME 3 trial included 428 patients with diabetes (28.5%). Patients with diabetes, especially those receiving insulin, had a higher risk of MACCE at 3 years compared with those without diabetes. Regarding relative treatment effect, the risk of MACCE was higher after FFR-guided PCI compared with CABG in both patients with diabetes (hazard ratio [HR], 1.44; 95% CI, 0.91-2.28; P = .12) and those without diabetes (HR, 1.50; 95% CI, 1.08-2.07; P = .02), with no significant interaction (P for interaction = .94). In patients with a low SYNTAX score (<23), there was no significant difference in MACCE between PCI and CABG, while in patients with an intermediate to high SYNTAX score (≥23), PCI had a higher risk of MACCE than CABG, regardless of diabetes status. CONCLUSIONS AND RELEVANCE: In this subgroup analysis of the FAME 3 randomized clinical trial, the relative benefit of CABG compared with FFR-guided PCI was similar among patients with and without diabetes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02100722.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Takahashi K, Otsuki H, Zimmermann FM, et al. FFR-Guided Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Diabetes. JAMA Cardiol. 2025. PMID: 40072460. doi:10.1001/jamacardio.2025.0095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。